Durham biotechnology company developing selective small-molecule TAK1 inhibitors for autoimmune, inflammatory, fibrotic, neurodegenerative, and infectious diseases.
At a glance
- Founded: 2016
- HQ: Durham
- Sector: Biotech
- Stage: Grant
- Affiliation: Duke
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Where the team studied
Filter the directory by schoolDuke University
- Scott ScarneoAlumPh.D., PharmacologySource
- Timothy HaysteadFacultyProfessor of Pharmacology and Cancer BiologySource
North Carolina State University
- Robert FreezeAlumM.B.A., Finance and EntrepreneurshipSource
University of North Carolina at Chapel Hill
- Philip HughesAlumB.S., ChemistrySource
Each line was checked against a primary source. Founder education is recorded for part of the directory, so a name missing here is a gap in what has been checked, not a statement that they studied somewhere else. Tell me what is missing.
Listed roles
All Triangle rolesChecking listed roles…